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The effect of dose on the pharmacokinetics of ciprofloxacin in serum and urine following single intravenous
doses of 100, 150, and 200 mg was studied in nine healthy volunteers. Mean peak levels in serum were 1.4, 2.0,
and 3.2 mg/liter for the 100-, 150-, and 200-mg doses, respectively. The data on concentrations in serum were
best described by a three-compartment pharmacokinetic model. The terminal half-life (from noncom-
partmental analysis) averaged between 4.2 and 4.6 h. Average urinary recovery ranged between 45.8 and
48.1%. The average renal clearance of ciprofloxacin was 2.9- to 3.4-fold greater than the measured creatinine
clearance. Total serum and renal clearances decreased with increasing dose; however, this was not statistically
significant (P > 0.05; repeated-measures analysis of variance). Ciprofloxacin was well tolerated by all subjects.
In this dose range, ciprofloxacin pharmacokinetics are independent of dose.
Ciprofloxacin is a new fluoroquinolone antibiotic with
potent activity against many clinically important human
pathogens (18). As with several newer agents of this class,
ciprofloxacin is well absorbed when administered orally and
attains bactericidal concentrations in serum and many body
fluids and tissues. The results of clinical trials with the oral
formulation have documented the efficacy of this agent (1);
studies with the parenteral formulation are in progress.
Nonlihear pharmacokinetic properties are often due to
saturation of renal, hepatic, or other excretory pathways.
This study was designed to characterize the excretion and
distribution of ciprofloxacin following intravenous admin-
istration and to assess the effect of dose size on phar-
macokinetic parameters. In addition, multicompartmental
pharmacokinetic models were used to describe the pharma-
cokinetics of extravascular distribution of ciprofloxacin.
MATERIALS AND METHODS
Voluitteers. Nine healthy men were studied. The mean (±
the standard deviation [SD]) age, height, and weight were as
follows: 23 (±3) years, 70.1 (±4.2) in. (1 in. = 2.54 cm), 81.5
(±9) kg. All subjects had a normal physical examination
(including assessment of visual acuity and color perception),
electrocardiogram, blood chemistries, hematology, and
urinalysis at screening and before and after each dose. All
sUbjects were in excellent health, had no known medical
disorders, and had not ingested any medications for at least
2 weeks before entry into the study. Alcohol-containing
beverages were Withheld for 72 h before each dose and for
the duration of sample collection. Volunteers fasted over-
night and for the first 4 h of the study. Informed consent was
obtained according to the guidelines of our institution.
Administration and sample collection. Each volunteer re-
* Corresponding author.
t Present address: Pfizer Central Research, Groton, CT 06340.
ceived three single, rising ciprofloxacin doses of 100, 150,
and 200 mg at exactly 1-week intervals. Doses were prepared
from ampoules containing 100 mg of ciprofloxacin (Miles
Pharmaceuticals, West Haven, Conn.), which was diluted in
normal saline to make a final volume of 100 ml. Each dose
was infused over 30 min into a peripheral vein with a
constant-rate infusion pump. Intravenous (i.v.) tubing and
catheters were flushed with at least 25 ml of saline at the
conclusion of the infusion to ensure complete delivery of the
dose.
Blood was collected from a second indwelling intermittent
i.v. infusion set (heparin lock) at the following times:
predose (time zero) and 15 min (midinfusion), 30 min (end of
infusion), 35, 40, and 50 min, and 1, 1.25, 1.5, 2, 2.5, 3, 3.5,
4.5, 6.5, 8.5, 10.5, 12.5, 16.5, 20.5, and 24.5 h after the start
of the infusion. Serum was separated from cells by centrif-
ugation, and aliquots were frozen. Urine samples were
collected and pooled during 0 to 1.5, 1.5 to 2.5, 2.5 to 3.5, 3.5
to 4.5, 4.5 to 6.5, 6.5 to 8.5, 8.5 to 10.5, 10.5 to 12.5, 12.5 to
16.5, 16.5 to 20.5, 20.5 to 24.5, 24.5 to 36.5, and 36.5 to 48.5
h after the start of the infusion. All urine and serum samples
were stored at -90°C until assay.
Drug assay. Ciprofloxacin concentrations in serum and
urine were determined by a new high-pressure liquid chro-
matography method developed in our laboratory. The mo-
bile phase consisted of acetonitrile-0.025 M phosphoric acid
buffer (8:92 [vol/vol]). The phosphate buffer was made with
phosphoric acid (high-pressure liquid chromatography
grade; Fisher Scientific Co., Medford, Mass.) and adjusted
to a pH of 3.0 with 40% tetrabutylammonium hydroxide
(Sigma Chemical Co., St. Louis, Mo.). This mixture was
prepared fresh daily with acetonitrile (high-pressure liquid
chromatography grade; Fisher) buffer, filtered through a
0.22-,um (pore size) membrane filter (GS; Millipore Corp.,
Bedford, Mass.), and degassed in an ultrasonic water bath.
The mobile phase was passed through a 10-,um, 25-cm C18
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Applied Science Div., State College, Pa.) at a flow rate of 1.5
ml/min. A guard column (Alltech) packed with 10-,um (diam-
eter) pellicular C18 packing was used to maintain analytical-
column performance. The guard column was repacked each
day by removing the top 1 cm of packing and replacing it
with new material. The mobile phase was monitored by a
fluorescence detector (GM 770; Schoeffel Instruments,
Westwood, N.J.) with an excitation wavelength of 274 nm
and an emission wavelength of 418 nm (range, R = 0.02).
The signal was recorded, and the peak height was deter-
mined with an integrator.
Stock solutions of ciprofloxacin (BAY 09867, lot 907337;
Miles Pharmaceuticals) at 10 jxg/ml were prepared fresh
daily in distilled water. Pipemidic acid (Sigma) at 100.0 and
5.0 ,ug/ml was prepared fresh daily in 1.0 N HCl and used as
an internal standard at these concentrations for assay of
urine and serum samples, respectively. Urine and serum
standards were prepared fresh daily by using the stock
solution of ciprofloxacin.
Standards and unknown serum samples were processed
by pipetting 500 RI1 of serum into a 1-ml disposable syringe
fitted with a 0.22-,um disposable filter (Duropore; Millipore).
Fifty microliters of internal standard was added to a syringe,
and the mixture was vortexed for 15 s. The filtrate was
collected, and 10 j.I was injected into the instrument. Urine
samples were prepared by vortexing thawed samples and
diluting an aliquot with an appropriate volume of phosphate
buffer to bring the concentration into the range of the
standard curve.
The column retention times for pipemidic acid and
ciprofloxacin were 3.8 and 5.8 min, respectively. Peak
heights were determined by the integrator, and ciprofloxacin
peak height-internal standard peak height ratios were calcu-
lated; these ratios showed a direct linear correlation with the
drug concentrations in known standards. Concentrations of
unknown samples were calculated from the serum standard
curves by least-squares regression. The sensitivity of the
assay in serum was 0.008 mg/liter. Linearity of cipro-
floxacin-internal standard peak height ratios was demon-
strated with ciprofloxacin concentrations in serum and urine
in the range of 0.01 to 1 and 0.1 to 20 mg/liter, respectively.
Within-day precision for three serum standards ranging in
concentration between 0.05 and 0.5 mg/liter (n = 5) was 2.4
to 5.2% (coefficient of variation). The accuracy (calculated
as [actual measured]/actual x 100%) of these standards was
+2.2 to 6.4%. Recovery of ciprofloxacin from serum was
96%. The ciprofloxacin serum standards were shown to be
stable for at least 11 days at -70°C (data not shown).
Pharmacokinetic and statistical analyses. Data on concen-
trations in serum were analyzed by using compartmental and
noncompartmental pharmacokinetic models. The areas un-
der the zero and first moments of the concentration-time
curves for serum were calculated by using the linear trape-
zoidal rule. The terminal slope (Xi) was identified by visual
inspection of plots and calculated by using least-squares
regression. Residual areas under the curve were determined
by dividing the last detectable concentration in serum by X,
(6). Total-body clearance, volume of distribution at steady
state, mean residence time, and noncompartmental half-life
were calculated by using standard equations corrected for an
i.v. infusion (6). Renal clearance was calculated as the
amount of drug excreted unchanged in urine during the urine
collection interval divided by the area under the correspond-
ing concentration-time curve for serum. The net renal secre-
tion clearance of ciprofloxacin was calculated by renal
clearance - (0.573 x measured creatinine clearance), where
0.573 is the fraction of ciprofloxacin unbound to serum
protein measured in a previous study (8).
Data on concentrations in serum were also analyzed by
using two- and three-compartment open pharmacokinetic
models by extended least-squares regression with an Ap-
plesoft version of the computer program MKMODEL (N.
Holford, University of Auckland School of Medicine,
Auckland, New Zealand, 1985), a variant of the program
available on the PROPHET computer network (10, 11). The
variance in predicted concentrations was modeled as yPWR
(power model), where PWR was constrained to be between
0 and 3. Macroscopic pharmacokinetic constants were used
in defining pharmacokinetic models; standard equations
were applied to correct for infusion time and calculate
microscopic pharmacokinetic rate constants (6). The good-
ness of fit of the two- or three-compartment body model to
the data was determined by using the Schwartz criterion,
defined as log likelihood - (K12 x ln N), where the log
likelihood is computed by using the objective function of the
extended least-squares regression and is a measurement of
how well the parameters in the model describe the data, K is
the total number of structural and variance model parame-
ters, and N is the number of observations (13).
The effect of dose on pharmacokinetic parameters was
assessed by using analysis of variance for repeated measure-
ments (12).
RESULTS
Mean concentrations in serum for all dose levels are
depicted in Fig. 1. The peak (+SD) concentrations in serum
for the 100, 150, and 200-mg doses were 1.4 (±0.6), 2.0
(±0.5), and 3.2 (±0.6) mg/liter, respectively. Concentrations
in serum declined rapidly immediately following the infu-
sion, with average concentrations falling below 1 mg/liter
within 30 min of completion of the infusion with all doses.
Following this rapid-distribution phase, a slow-elimination
phase with an average terminal half-life of between 4.2 and
4.6 h was observed.
Noncompartmental pharmacokinetic analysis of data on
concentrations in serum is summarized in Table 1. Total-
body clearance and its two components, renal and nonrenal
clearance, tended to decrease with increasing dose; how-
ever, this difference was not statistically significant (P >
0.05). The volume of distribution (steady state) of cipro-
floxacin was large and averaged between 2.0 and 2.4
liters/kg, with no dose dependence (P > 0.05).
Urinary concentrations of ciprofloxacin and the excretion
rate are depicted in Table 2 and Fig. 2, respectively. Over
25% of the dose was excreted unchanged during the first 4 h.
Concentrations in urine were high, with clinically significant
concentrations still present at 48 h after the dose. The
average urinary recovery of ciprofloxacin at 48 h ranged
between 45.8 and 48.1% and was not dose dependent (Table
1; P > 0.05). On average, the renal clearance of ciprofloxacin
was 2.9- to 3.4-fold greater than the measured creatinine
clearance. The mean (±SD) net renal secretion clearance
values were 3.83 (±1.10), 3.61 (±1.14), and 3.02 (±0.92)
m/min per kg for the 100-, 150-, and 200-mg doses, respec-
tively; the differences in these values were not statistically
significant (P > 0.05).
Analysis of serum data with a three-compartment pharma-
cokinetic model is depicted in Table 3. On the basis of the
Schwartz criterion, most of the data sets were best described
by using the three-compartment model; this was particularly
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FIG. 1. Mean (+SD) ciprofloxacin concentrations in serum in
nine healthy volunteers following a single 30-min i.v. infusion of
200-mg (A), 150-mg (B), and 100-mg (C) doses.
TABLE 1. Noncompartmental pharmacokinetic analysis of
ciprofloxacin excretion data for serum and urine
Mean (± SD) value at a dose of:
Parameter (unit)a
100 mg 150 mg 200 mg
AUC (mg * h/liter) 2.24 (0.54) 3.36 (0.74) 5.17 (0.87)
Vss (liters/kg) 2.17 (0.45) 2.40 (0.61) 2.00 (0.39)
FE (%) 48.1 (5.6) 45.8 (5.9) 46.4 (6.9)
CL (ml/min per kg) 9.60 (2.09) 9.57 (2.02) 8.15 (1.21)
CLNR (ml/min per kg) 4.99 (1.18) 5.17 (1.11) 4.34 (0.71)
CLR (ml/min per kg) 4.61 (1.14) 4.40 (1.16) 3.80 (0.87)
CLR-S (mi/min per kg) 3.83 (1.10) 3.61 (1.14) 3.02 (0.92)
Mean residence time (h) 3.92 (1.81) 4.23 (0.80) 4.10 (0.50)
tl/2eff (h) 2.72 (0.82) 2.93 (0.56) 2.84 (0.35)
t1/2z (h) 4.21 (0.89) 4.62 (1.19) 4.22 (0.63)
a Abbreviations: AUC, area under the concentration-time curve for serum;
FE, fraction of the dose excreted unchanged in urine; V., volume of
distribution at steady state; CL, CLR, CLR-S, and CLNR, total serum, total
renal, net renal secretion, and nonrenal clearances, respectively; tl/2eff,
noncompartmental (or effective) half-life; and tl/2k,, half-life of the terminal
slope.
TABLE 2. Mean (±SD) ciprofloxacin concentrations
in urine in nine volunteers
Collection interval Mean (±SD) concn (mg/liter) in urine at a dose of:
(h after start of
infusion) 100 mg 150 mg 200 mg
0-1.5 191.7 ± 95.9 210.6 ± 136.8 256.5 ± 169.6
1.5-2.5 53.8 ± 49.4 60.8 ± 33.7 119.0 ± 82.0
2.5-3.5 41.9 ± 24.7 59.5 ± 39.1 81.9 ± 57.9
3.5-4.5 27.4 ± 26.4 28.9 ± 34.4 47.4 ± 54.1
4.5-6.5 14.4 ± 8.8 21.0 ± 17.3 28.1 ± 28.9
6.5-8.5 10.1 ± 6.8 13.3 ± 8.8 26.7 ± 24.6
8.5-10.5 7.4 ± 7.5 7.6 ± 5.5 22.1 ± 20.2
10.5-12.5 5.1 ± 4.2 8.6 + 6.2 15.4 ± 11.9
12.5-16.5 5.1 ± 3.4 4.4 ± 2.4 11.1 ± 9.0
16.5-20.5 4.4 ± 3.6 7.6 ± 6.5 7.2 ± 3.4
20.5-24.5 2.6 ± 3.0 3.9 ± 2.4 5.3 ± 3.6
24.5-36.5 0.8 ± 0.4 1.1 ± 0.5 1.4 ± 1.2
36.5-48.5 0.3 ± 0.1 1.9 ± 4.2 0.9 ± 0.8
were identified. A rapidly equilibrating peripheral compart-
ment (V2) accounted for approximately one-fourth to one-
third of the total apparent of volume of distribution. A
deep-tissue compartment (V3) was large and was associated
with relatively slow intercompartmental clearance.
Overall, ciprofloxacin was well tolerated by all of the
volunteers. There was no laboratory evidence of drug intol-
erance. Extravasation of infusate containing ciprofloxacin
occurred in one subject during the last 5 min of infusion of
the 150-mg dose. Slight erythema, induration, and tender-
ness at the infusion site were observed. Local treatment with
warm compresses was applied, and the induration and
tenderness subsided within a few hours. No further systemic
or local complications were noted in this subject.
DISCUSSION
Statistical analysis of these data by analysis of variance
demonstrated that ciprofioxacin pharmacokinetics are linear
and not dose dependent in the narrow dosage range studied,
regardless of the type of pharmacokinetic analysis applied;
this is similar to the conclusions reached in other studies of
i.v. doses in this range (3, 5, 8, 9). The values for total
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FIG. 2. Cumulative amounts (mean + SD) of ciprofloxacin ex-
creted unchanged in urine for 100-, 150-, and 200-mg doses with
time.
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TABLE 3. Ciprofloxacin pharmacokinetic parameters with
a three-compartment pharmacokinetic model
Parameter Mean (±SD) value at a dose ofb:
(unit)a 100 mg 150 mg 200 mg
klo (h-1) 2.02 (1.26) 2.20 (1.11) 3.61 (1.99)
k12 (h-1) 4.48 (4.56) 5.14 (4.08) 8.57 (5.48)
k13 (h-1) 1.00 (1.12) 1.93 (1.28) 4.31 (3.60)
k2l (h-l1) 1.60 (0.92) 2.44 (1.24) 3.35 (2.74)
k3l (h-1) 0.19 (0.10) 0.33 (0.25) 0.36 (0.17)
tl/2X1 (h) 0.11 (0.06) 0.08 (0.04) 0.06 (0.04)
tl/2X2 (h) 1.64 (1.18) 0.87 (0.53) 0.92 (0.84)
tl/203 (h) 7.40 (3.60) 5.69 (2.24) 4.90 (1.75)
V,, (liters/kg) 2.89 (1.06) 2.53 (0.87) 1.98 (0.39)
V1 (liters/kg) 0.40 (0.56) 0.30 (0.13) 0.20 (0.14)
V2 (liters/kg) 0.91 (0.56) 0.60 (0.36) 0.58 (0.44)
V3 (liters/kg) 1.59 (0.94) 1.63 (0.66) 1.20 (0.47)
CLT (ml/min per kg) 9.21 (2.46) 9.13 (2.01) 7.96 (1.14)
CLInter 1-2 (ml/min 20.67 (15.84) 20.65 (11.60) 20.25 (7.82)
per kg)
CLInter 1-3 (ml/min 4.91 (3.88) 8.62 (6.33) 7.66 (4.94)
per kg)
a There was no effect of dose on any of these parameters (P > 0.05; analysis
of variance). Abbreviations: klo, k12, k13, k2l, and k3l, intercompartmental
transfer rate constants; t1nZ}, half-life of the individual slope; Vs,, V1, V2, and
V3, steady-state volume of distribution and volumes of the central and two
peripheral compartments, respectively; CLT, total serum clearance; CLIn,tr,
intercompartmental clearance.
b Data for the 100- and 200-mg doses are for nine volunteers, and those for
the 150-mg dose are for eight volunteers, as the data from one subject could
not be described by this model.
range reported here are in agreement with those reported by
others (3, 7-9, 16, 17) but are higher than those calculated by
Drusano et al. (5).
Studies using radiolabeled drug have shown that cipro-
floxacin is excreted unchanged in urine and feces and as four
metabolites (2). Although not statistically significant, a trend
toward decreasing clearance was observed in this study.
Both nonrenal and renal ciprofloxacin clearances decreased
with higher doses by approximately 15 to 20% with the
higher dose. Saturation of nonrenal clearance may occur
because of changes in the rate of hepatic biotransformation
or decreased excretion into the gastrointestinal tract through
biliary or other routes. Dose-ranging studies using large oral
doses that might readily saturate hepatic metabolism during
the first pass to the liver have not demonstrated changes with
increasing dose (9, 15). However, Drusano et al. were able to
demonstrate a higher total clearance from serum, particu-
larly of the nonrenal component, with a prolonged infusion
of 200 mg over 4 h than with the same dose infused over 30
min (5). Insufficient data exist to determine which of these
mechanisms is responsible for the subtle changes in nonrenal
clearance observed in these studies.
Renal excretion of ciprofloxacin is predominantly due to
net renal tubular secretion of the drug. Although not statis-
tically significant, a trend toward lower renal clearance
values with increasing doses was observed in this study as in
other studies (8, 9, 15). This may be due to saturable renal
tubular secretion of ciprofloxacin, as reflected in decreasing
net renal tubular secretion clearance values (Table 1).
Ciprofloxacin distribution to the extravascular space is
extensive, as reflected by the large volume of distribution
and high concentrations of ciprofloxacin in extravascular
fluids and tissues (17, 18). Our analysis with a three-
compartmental pharmacokinetic model quantified the ap-
proximate sizes and the kinetics of distribution into two
peripheral compartments. The rapidly equilibrating compart-
ment (V2) has a high intercompartmental clearance rate; this
accounts for the rapid decline in ciprofloxacin concentra-
tions in serum immediately following the conclusion of drug
infusion. A third, slowly equilibrating (or deep) tissue com-
partment with relatively slow intercompartmental clearance
contributes to the prolonged terminal half-life (ca. 4 to 5 h) of
ciprofloxacin.
Analysis of serum data by different pharmacokinetic meth-
ods has resulted in some confusion regarding estimates of
some of the pharmacokinetic parameters (e.g., half-life) of
the new fluoroquinolones. In contrast to previous studies,
we performed our compartmental analysis by using extended
least-squares regression, which has been demonstrated to be
more precise and less biased in the estimation of pharmaco-
kinetic parameters than other least-squares regression ap-
proaches (10, 14). Extended least-squares regression analy-
sis eliminates the necessity of choosing proper weights for
analysis of data, which can greatly influence estimates of
certain pharmacokinetic parameters (e.g., terminal half-life)
whose estimation is largely based on drug concentrations
measured in the lower range of assay sensitivity, where
precision and accuracy are often poorest. In addition, the
value of the terminal half-life may vary according to whether
the analysis is conducted with a two- or three-compartment
pharmacokinetic model. We used an objective method (the
Schwartz criterion) as the basis for determining which model
best described the data with the least number of structural-
model parameters. This statistic is similar to the Akaike
information criterion (19); however, it differs in its use of
likelihood ratios rather than the sum of squares. Analysis
demonstrated that the three-compartment model was supe-
rior to the two-compartment model in most data sets,
primarily because of better precision in predicting concen-
trations in serum during hour 1 following the end of drug
infusion. The superiority of the three-compartment model in
describing the pharmacokinetics of ciprofloxacin following
i.v. infusion has also been noted by others using different
criteria (4, 5, 8). However, despite the superiority of the
three-compartment model in describing serum data, esti-
mates of the major pharmacokinetic parameters (i.e., clear-
ance, volume of distribution, and half-life) were similar with
both methods, perhaps because of frequent sampling in the
lower concentration ranges (i.e., the terminal slope).
In summary, we have demonstrated the linearity of
ciprofloxacin pharmacokinetics in normal volunteers within
the 100- to 200-mg dosage range following i.v. administra-
tion. Further studies using higher doses are needed to
confirm linear pharmacokinetic properties with larger doses
of this drug.
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